Every Form 4 that Arcadia Biosciences, Inc. (RKDA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow RKDA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RKDA filings page.
Arcadia Biosciences, Inc. (RKDA) reported that director Amy Yoder received a grant of stock options covering 10,000 shares of common stock on September 10, 2026. The options have an exercise price of $0.46 per share and expire on September 10, 2036. They vest 100% on the earlier of September 10, 2027 or the next Annual Meeting of Stockholders, subject to her continued service, after which her directly held derivative position reported in this grant totals 23,442 options.
Arcadia Biosciences, Inc. (RKDA) reported that director Kevin Comcowich received a grant of 23,000 stock options on September 10, 2026, with an exercise price of $0.46 per share and an expiration date of September 10, 2036. These options vest 100% on the earlier of September 10, 2027 or the company’s next Annual Meeting of Stockholders, subject to his continued service, bringing his reported outstanding option holdings to 54,042 options. No Rule 10b5-1 trading plan is reported for this award.
Arcadia Biosciences, Inc. (RKDA) reported that director Gregory D. Waller received a grant of stock options for 10,000 shares of common stock on September 10, 2026. The options have an exercise price of $0.46 per share, expire on September 10, 2036, and leave him with 23,338 options held directly after the grant. The award will become 100% vested and exercisable on the earlier of September 10, 2027 or the date of the company’s next Annual Meeting of Stockholders, subject to his continued service, and no Rule 10b5-1 trading plan is reported.
Arcadia Biosciences, Inc. (RKDA) reported that director Murray Lilian Shackelford received a grant of 10,000 stock options on September 10, 2026. The options have an exercise price of $0.46 per share and expire on September 10, 2036. They become 100% vested and exercisable on the earlier of September 10, 2027 or the date of Arcadia’s next Annual Meeting of Stockholders, subject to continued service. Following this grant, Shackelford holds 23,287 derivative securities directly.